Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023

Details

• Alternative Title:
  MMWR. Morbidity and Mortality Weekly Report, Vol. 72, No. 42, October 20, 2023: Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023
• Personal Author:
  Regan, Joanna J. ; Moulia, Danielle L. ; Link-Gelles, Ruth ; Godfrey, Monica ; Mak, Josephine ; Najdowski, Morgan ; Rosenblum, Hannah G. ; Shah, Melisa M. ; Twentyman, Evelyn ; Meyer, Sarah ; Peacock, Georgina ; Thornburg, Natalie ; Havers, Fiona P. ; Saydah, Sharon ; Brooks, Oliver ; Talbot, H. Keipp ; Lee, Grace M. ; Bell, Beth P. ; Mahon, Barbara E. ; Daley, Matthew F. ; Fleming-Dutra, Katherine E. ; Wallace, Megan
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.) ; Advisory Committee for Immunization Practices (ACIP)
• Description:
  COVID-19 vaccines protect against severe COVID-19– associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, and waning vaccine effectiveness has been noted, vaccine formulations and policies have been updated to provide continued protection against severe illness and death from COVID-19. Since September 2022, bivalent mRNA COVID-19 vaccines have been recommended in the United States, but the variants these vaccines protect against are no longer circulating widely. On September 11, 2023, the Food and Drug Administration (FDA) approved the updated (2023–2024 Formula) COVID-19 mRNA vaccines by Moderna and Pfizer-BioNTech for persons aged ≥12 years and authorized these vaccines for persons aged 6 months–11 years under Emergency Use Authorization (EUA). On October 3, 2023, FDA authorized the updated COVID-19 vaccine by Novavax for use in persons aged ≥12 years under EUA. The updated COVID-19 vaccines include a monovalent XBB.1.5 component, which is meant to broaden vaccine-induced immunity and provide protection against currently circulating SARS-CoV-2 XBB-sublineage variants including against severe COVID-19–associated illness and death. On September 12, 2023, the Advisory Committee on Immunization Practices recommended vaccination with updated COVID-19 vaccines for all persons aged ≥6 months. These recommendations will be reviewed as new evidence becomes available or new vaccines are approved and might be updated.
  
  With erratum attached.
  
  
• Content Notes:
  Stacks staff attached the erratum as the last page of this PDF file.
• Subjects:
  COVID-19 Vaccines Immunization Immunization, Secondary SARS-CoV-2 Vaccination Vaccine Development Vaccines, Combined
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm7242e1
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Publisher:
  Centers for Disease Control and Prevention
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  United States
• Rights:
  Public Domain
• CIO:
  Office of Science
• Division:
  Morbidity and Mortality Weekly Report
• Topic:
  Diseases & Conditions
• Location:
  North America
• Pages in Document:
  8 pdf pages
• Volume:
  72
• Issue:
  42
• Citation:
  Suggested citation for this article: Regan JJ, Moulia DL, Link-Gelles R, et al. Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023. MMWR Morb Mortal Wkly Rep 2023;72:1140–1146. DOI: http://dx.doi.org/10.15585/mmwr.mm7242e1.
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:961882f138682fbf30863bc86b7cad25851d40342b6008af0d7454dbe699084ad98c55ec0d4828eddeb6ced432a0eef2c9e0e5b3cf75dd30ea19cfea626088cd
• Download URL:
  https://stacks.cdc.gov/view/cdc/255748/cdc_255748_DS1.pdf
• File Type:
  [PDF - 803.59 KB ]